Skip to main content
Premium Trial:

Request an Annual Quote

Agilent and ExonHit Partner to Develop Microarray for Splice Variants

NEW YORK, Nov. 15 (GenomeWeb News) - Agilent Technologies will combine its microarray platform with ExonHit's alternative RNA splicing in an attempt to develop an array technology that can monitor the expression of splice variants, the companies said today.

 

The companies presented results from an experimental splicing array of G-protein coupled receptors, which was designed by ExonHit and produced by Agilent, at the Splicing 2004 meeting, held in September in Bethesda, Md.

 

That array was bale to detect multiple isoforms of several genes, and "showed good reproducibility and specificity," the companies said in a statement today. Agilent and ExonHit "are expected to work with early test sites to generate additional experimental results," the firms said.

Financial terms of the agreement were not disclosed.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.